Funding Rounds

F2G

F2G Series D Round, September 2024

Oral antifungal therapy developer to treat life-threatening rare fungal infections

View Company Profile

Summary

Stage: Series D

Raised Amount: $100.00M

Raised Date: 2024-09-12

Investors

Advent Life Sciences
( 35 )

Advent Life Sciences
( 35 )

Intermediate Capital Group
( 43 )

Intermediate Capital Group
( 43 )

Intermediate Capital Group
( 43 )

Novo Holdings A/S
( 1 )

Forbion Capital Partners
( 34 )

Forbion Capital Partners
( 34 )

Sofinnova Partners
( 36 )

Sofinnova Partners
( 36 )

Sofinnova Partners
( 36 )

Sofinnova Partners
( 36 )

Merifin Capital
( 1 )

Morningside Ventures
( 1 )

Blue Owl
( 39 )

AMR Action Fund
( 26 )